CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Annals of Clinical and Translational Neurology2016Vol. 3(3), pp. 154–165
Citations Over TimeTop 1% of 2016 papers
Shorena Janelidze, Henrik Zetterberg, Niklas Mattsson, Sebastian Palmqvist, Hugo Vanderstichele, Olof Lindberg, Danielle van Westen, Erik Stomrud, Lennart Minthon, Kaj Blennow, the Swedish BioFINDER study group, Oskar Hansson
Abstract
The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to detect brain amyloid deposition in prodromal AD and to differentiate AD dementia from non-AD dementias. The ratios reflect AD-type pathology better, whereas decline in CSF Aβ42 is also associated with non-AD subcortical pathologies. These findings strongly suggest that the ratios rather than CSF Aβ42 should be used in the clinical work-up of AD.
Related Papers
- → Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study(2016)79 cited
- → Ubiquitin in Cerebrospinal Fluid in Alzheimer ’s Disease and Vascular Dementia(1994)41 cited
- Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report).(2004)
- → P2‐220: Patients with dementia with Lewy bodies have increased calcium and magnesium levels in CSF(2008)
- → A Study of Auditory Hallucinations in Dementia with Lewy Bodies(2023)